troglitazone has been researched along with Metabolic Syndrome in 8 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We analyzed data from the Diabetes Prevention Program (DPP) for 2,476 adults in 1996-1999 with prediabetes randomized to receive treatment with lifestyle modification, metformin, or placebo for 2-3 years and followed through 2014 for T2DM and CVD outcomes." | 5.27 | Use of a Metabolic Syndrome Severity ( DeBoer, MD; Filipp, SL; Gurka, MJ, 2018) |
| "Troglitazone was the first drug which reached the market." | 2.41 | [Thiazolidinediones--a new class of oral antidiabetic drugs]. ( Csermely, P; Jermendy, G, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Banerjee, S | 1 |
| Talukdar, I | 1 |
| Banerjee, A | 1 |
| Gupta, A | 1 |
| Balaji, A | 1 |
| Aduri, R | 1 |
| DeBoer, MD | 1 |
| Filipp, SL | 1 |
| Gurka, MJ | 1 |
| Moreno Sánchez, D | 1 |
| Grant, RW | 1 |
| Meigs, JB | 1 |
| Maraldi, NM | 1 |
| Capanni, C | 1 |
| Mattioli, E | 1 |
| Columbaro, M | 1 |
| Squarzoni, S | 1 |
| Parnaik, WK | 1 |
| Wehnert, M | 1 |
| Lattanzi, G | 1 |
| Khashab, M | 1 |
| Chalasani, N | 1 |
| Iwasaki, Y | 1 |
| Takayasu, S | 1 |
| Nishiyama, M | 1 |
| Tsugita, M | 1 |
| Taguchi, T | 1 |
| Asai, M | 1 |
| Yoshida, M | 1 |
| Kambayashi, M | 1 |
| Hashimoto, K | 1 |
| Jermendy, G | 1 |
| Csermely, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| [NCT00004992] | Phase 3 | 3,234 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| Diabetes Prevention Program Outcomes Study[NCT00038727] | Phase 3 | 2,779 participants (Actual) | Interventional | 2002-09-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Primary outcome for years 2002-2008 defined according to American Diabetes Association criteria (fasting plasma glucose level >= 126 mg/dL [7.0 mmol/L] or 2-hour plasma glucose >= 200 mg/dL [11.1 mmol/L], after a 75 gram oral glucose tolerance test (OGTT), and confirmed with a repeat test). (NCT00038727)
Timeframe: Outcomes were assessed from 1996-2008 (approximately 12 years including 6 years of DPP).
| Intervention | diabetes incidence (cases per 100 person (Number) |
|---|---|
| 1 Original Lifestyle | 5.3 |
| 2 Original Metformin | 6.4 |
| 3 Original Placebo | 7.8 |
All cause-mortality through clinic reports and National Death Index search (NCT00038727)
Timeframe: Outcomes were assessed throughout follow-up from 1996 to 2022. National Death Index search conducted in 2019 using early release data as of Dec 2018.
| Intervention | Participants (Count of Participants) |
|---|---|
| 1 Original Lifestyle | 158 |
| 2 Original Metformin | 152 |
| 3 Original Placebo | 143 |
Aggregate microvascular disease is defined as the average prevalence of 3 components: (1) retinopathy measured by photography (ETDRS of 20 or greater); (2) neuropathy detected by Semmes Weinstein 10 gram monofilament, and (3) nephropathy based on estimated glomerular filtration rate (eGFR by chronic kidney disease (CKD-Epi) equation ) (<45 ml/min, confirmed) and albumin-to-creatinine ratio in spot urine (> 30mg/gm, confirmed). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | average percentage of participants (Number) |
|---|---|
| 1 Original Lifestyle | 11.3 |
| 2 Original Metformin | 13 |
| 3 Original Placebo | 12.4 |
Measured using coronary artery calcification (CAC). (NCT00038727)
Timeframe: Outcomes were assessed from 2012-2013 (approximately 2 years).
| Intervention | CAC geometric mean in AU (Geometric Mean) | |
|---|---|---|
| Men | Women | |
| 1 Original Lifestyle | 70.1 | 6.0 |
| 2 Original Metformin | 40.2 | 6.1 |
| 3 Original Placebo | 63.7 | 5.3 |
4 reviews available for troglitazone and Metabolic Syndrome
| Article | Year |
|---|---|
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fa | 2005 |
Management of the metabolic syndrome.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Di | 2005 |
Use of insulin sensitizers in NASH.
Topics: Alanine Transaminase; Chromans; Fatty Liver; Humans; Insulin Resistance; Metabolic Syndrome; Metform | 2007 |
[Thiazolidinediones--a new class of oral antidiabetic drugs].
Topics: Animals; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metabolic Syndrome; Piogl | 2001 |
1 trial available for troglitazone and Metabolic Syndrome
| Article | Year |
|---|---|
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
Use of a Metabolic Syndrome Severity
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Progress | 2018 |
3 other studies available for troglitazone and Metabolic Syndrome
| Article | Year |
|---|---|
Type II diabetes mellitus and obesity: Common links, existing therapeutics and future developments.
Topics: Adipogenesis; Diabetes Mellitus, Type 2; Glucose; Humans; Hypoglycemic Agents; Insulin Resistance; M | 2019 |
A pathogenic mechanism leading to partial lipodistrophy and prospects for pharmacological treatment of insulin resistance syndrome.
Topics: Adipocytes; Body Fat Distribution; Cell Differentiation; Chromans; Humans; Insulin Resistance; Lamin | 2007 |
Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Anticholesteremic Agents; Base Sequence; Cell | 2008 |